2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
The goal of this study is to test the effectiveness of using the ArmAssist and Antari Homecare platform at home on upper extremity function in chronic stroke patients.Secundairy objectives are:- To evaluate the user-friendliness of the ArmAssist and…